Abstract Details

Title Placental transmission of MOG-IgG to neonate from mother with MOGAD

Topic Autoimmune Neurology

Presentation(s) P13 - Poster Session 13 (8:00 AM-9:00 AM)

Poster/Presentation
Number 6-026

Objective To investigate for transplacental transmission of myelin oligodendrocyte glycoprotein (MOG)-IgG from mother to neonate and quantitate duration of maternal MOG-IgG through testing of serial samples in an infant.

Background MOG antibody-associated disease (MOGAD) is a CNS-inflammatory demyelinating disease with a median age of onset of 20-30 years. Thus, women of childbearing age are commonly affected, and the postpartum period can be a time of increased risk of relapse. To our knowledge, no cases of neonatal MOGAD have been reported to date.

Design/Methods We studied transmission of MOG-IgG from mother to neonate in a patient with MOGAD with a history of seropositivity for MOG-IgG. Using an in-house MOG-transfected cell-based flow cytometry assay, we measured titer of the antibody in serum of the mother, cord blood and newborn at time of birth. We tested monthly serial samples to quantitate duration of maternal MOG-IgG in the baby.

Results The patient first developed MOGAD in 2005 at the age of 16, when she had an episode of acute disseminated encephalomyelitis. She subsequently had a relapse of myelitis and optic neuritis for which she received plasma exchange. She delivered at age 32. She had not been on any treatments in the 6 weeks prior to delivery. One month prior to delivery, the mother was positive for MOG-IgG (titer 1:20). At delivery, the mother was MOG-IgG negative, baby and cord blood were positive for MOG-IgG (titer 1:20). The baby was followed up for eight months and did not have any clinical features of MOGAD. Both mother and baby were negative for MOG-IgG at one month and two months post-delivery.

Conclusions Maternal MOG-IgG can be passively transferred to the fetus through the placenta and positivity in the baby occurred despite being below the threshold for detection in the mother. MOG-IgG in the baby was transient and without clinical manifestations.

Authors/Disclosures
Vyanka Redenbaugh, MB BCh BAO (Mayo Clinic) PRESENTER	Dr. Redenbaugh has nothing to disclose.
John Chen	John Chen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. John Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. John Chen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB.
Jessica A. Sagen, MA (Mayo Clinic)	Ms. Sagen has nothing to disclose.
Sean J. Pittock, MD, FAAN (Mayo Clinic Dept of Neurology)	Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from NIH. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received publishing royalties from a publication relating to health care.
Eoin P. Flanagan, MBBCh, FAAN (Mayo Clinic)	The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Merck. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology that is relevant to AAN interests or activities.

��ɫ��

��ɫ��